Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
Visualizing the Role of Antipsychotics in the Management of Schizophrenia: What is the Role of TAAR1?
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmacy Technician Credit)
2.0 Credits / Human Trafficking
Optimizing the Utilization of Targeted Therapies in CLL: Considerations and Insights for the Managed Care Professional
1.5 Credit / Oncology
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
Improving Pharmacists' Knowledge of Endometrial Cancer and Solutions for Equity and Medication Access
1.5 Credits / Endocrinology, Diabetes & Metabolism, Oncology
New and Emerging Therapies for the Treatment of Non-alcoholic Steatohepatitis: The Role of the Pharmacist in Early Identification and Clinical Intervention
1.5 Credits / Nephrology
The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.
Jacinda Abdul-Mutakabbir, PHARMD, MPH, AAHIVP, leads a conversation on the importance of vaccination in the defense and protection against viral infections, such as the flu.
Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, shares her thoughts on the changing perception of influenza and influenza vaccination post the COVID-19 pandemic.
Experts conclude their discussion on the efficacy and safety study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on possible dosing strategies and key takeaways from this study.
Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.
Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.
Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.
Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, discuss the initial efficacy data of the study on nirsevimab for Respiratory Syncytial Virus (RSV) and how it compared to placebo.
Tina Tan, MD, FAAP, FIDSA, FPIDS, presents the background, objectives, and methods of a recent study on the efficacy and safety of nirsevimab for Respiratory Syncytial Virus (RSV) in late-preterm and term infants.
Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the prevalence of Respiratory Syncytial Virus (RSV) and prior preventative gaps. They also discuss the recent FDA-approval of nirsevimab for late-preterm and term infants.